Incyte and Innocare announce collaboration and license agreement for Tafasitimab in Greater China
Clients Incyte Corporation
Jones Day represents Incyte Corporation in an exclusive license out of rights to conduct clinical trials, seek regulatory approval, and commercialize products containing Tafasitamab, an anti-CD19 monoclonal antibody, in Greater China. The license includes a sublicense to rights licensed to Incyte from MorphoSys, which has obtained approval for the product under the trademark MONJUVI®. The agreement includes coordinated clinical trial efforts, cost sharing, as well as reversionary and co-promotion rights of Incyte and a parent guarantee by Innocare.